Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Jorge Cortes, ASH 2022: New agents in relapsed or refractory acute myeloid leukaemia

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 5th 2023

Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses his highlights from the recent ASH 2022 conference, including two new agents that look promising in early studies on patients with relapsed or refractory acute myeloid leukaemia.

Abstracts discussed:

Abstract 63: ‘The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study‘ (00:10-02:20)

Abstract 64: ‘Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia‘ (02:20-03:46)

Disclosures: Jorge Cortes is a consultant for Novartis, Pfizer, Takeda, Sun Pharma and Rigel. He has received grant/research support from Novartis and Sun Pharma, and is on the advisory board for Novartis.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 64th ASH Annual Meeting & Exposition

Access more Leukaemia content here

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup